Literature DB >> 7749854

Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL.

C Bergmark1, R Wu, U de Faire, A K Lefvert, J Swedenborg.   

Abstract

Oxidative modification of LDL has been proposed as an early and crucial step in the development of atherosclerosis, and antibodies against such modified LDL are found in both healthy individuals and patients with atherosclerosis. In this study, 62 patients who were surgically treated for peripheral arterial occlusive disease below the age of 50 were investigated and compared with age- and sex-matched healthy individuals in a case-control study. Autoantibodies against oxidized LDL were measured with an enzyme-linked immunosorbent assay method. Risk factors such as smoking, hypertension, family history of premature cardiovascular events, and lipoprotein levels were also determined. The patients had significantly higher levels of autoantibodies against oxidized LDL; significantly higher levels of total cholesterol, LDL cholesterol, triglycerides, and apo A-I; and significantly lower levels of HDL cholesterol than did control subjects. In multivariate analyses autoantibodies against oxidized LDL discriminated better between patients and control subjects than did any of the different lipoprotein analyses. Among patients, the presence of hypertension and a family history of cardiovascular events were the only factors significantly associated with increased levels of autoantibodies against oxidized LDL.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7749854     DOI: 10.1161/01.atv.15.4.441

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  45 in total

1.  Cardiolipin is a normal component of human plasma lipoproteins.

Authors:  H Deguchi; J A Fernandez; T M Hackeng; C L Banka; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

2.  Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL.

Authors:  B P Swets; D A Brouwer; J W Tervaert
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  The autoantibody repertoire against copper- or macrophage-modified LDL differs in normolipidemics and hypercholesterolemic patients.

Authors:  Eva C Fernvik; Daniel F J Ketelhuth; Momtchilo Russo; Magnus Gidlund
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.317

4.  Attenuated atherosclerotic lesions in apoE-Fcγ-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells.

Authors:  Hang Pong Ng; Ramona L Burris; Shanmugam Nagarajan
Journal:  J Immunol       Date:  2011-10-31       Impact factor: 5.422

5.  Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.

Authors:  W Palinski; S Hörkkö; E Miller; U P Steinbrecher; H C Powell; L K Curtiss; J L Witztum
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 6.  Intravenous immunoglobulin and atherosclerosis.

Authors:  Eiji Matsuura; Kazuko Kobayashi; Katsumi Inoue; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

7.  Relation between plasma oxLDL antibodies and oxLDL in the circulation.

Authors:  Yan Wang; Xueqiang Fang; Shumei Wang; Yueqiu Feng; Jinghai Yin
Journal:  Inflammation       Date:  2006-12-02       Impact factor: 4.092

Review 8.  Vaccines for cholesterol management.

Authors:  Charles W Rittershaus
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

Review 9.  ACP Broad Sheet no 151: September 1997. Investigation of dyslipidaemias.

Authors:  A F Winder; W Richmond; D T Vallance
Journal:  J Clin Pathol       Date:  1997-09       Impact factor: 3.411

10.  Autoantibodies against oxidized low-density lipoprotein and lipid profile in patients with chronic periaortitis: case-control study.

Authors:  E F H van Bommel; L J H van Tits; E A van den Berg; J Prins; A F H Stalenhoef
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.